Arbutus reports preliminary AB-729 + IFN data at EASL; HBsAg declines seen

Arbutus Biopharma Corp

Mean HBsAg decline of 1.6 log10 at week 24 during AB-729 lead-in phase.
93% of patients (38/41) achieved HBsAg <100 IU/mL during treatment period.
Four patients reached HBsAg below LLOQ during IFN treatment; no sustained seroclearance yet.
No serious adverse events, discontinuations, or AB-729-related discontinuations reported.
Trial ongoing; three patients evaluated to stop NA therapy, one met criteria to stop.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.